구조모아 (StructureMoa)항암 chemical structure spider web
방문CARsgen Therapeutics Co.Ltd.
CAR-T cells chimeric antigen receptor T cells(CARsgen Therapeutics Co., Ltd.)은 FRα 표적 세포·유전자 치료로, AML; Refractory/Relapse Acute Myeloid Leukemia 영역에서 개발·상용화 중입니다. 작용기전: targeting B cell maturation antigen. Phase 1 안전성·PK 탐색 단계입니다. PFS: 0.99. 차별점: novel bridging strategies to eliminate MRD and enable transplant are urgently needed.
구조화 카탈로그 레코드입니다. Curated Core만큼 깊게 검토되지 않았습니다.
구조화 데이터
FRα
AML; Refractory/Relapse Acute Myeloid Leukemia
Recruiting
2026-08-19
Data Confidence · Medium
Development Signal · Watch
bispecific antibodies, and chimeric antigen receptor T cells
lentiviral expression vector and removed epitope tags used to discriminate between CAR and
humanized antibody capable of recognizing both LILRB3 and LILRB4
novel bridging strategies to eliminate MRD and enable transplant are urgently needed
targeting B cell maturation antigen
cytokine release syndrome occurred on day 3 and resolved with management; no neurotoxicity was observed
biomarker-driven methods were among the clinically orientated themes that emerged from foundational and precl
resistance to dominant suppressive pathways such as TGF-β and adenosine signalling, improved trafficking and tissue penetration
구조화 데이터
xenograft-bearing NSG mice
mouse
PD
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.
CARsgen Therapeutics Co.Ltd.
CAR-T cells chimeric antigen receptor T cells(CARsgen Therapeutics Co., Ltd.)은 FRα 표적 세포·유전자 치료로, AML; Refractory/Relapse Acute Myeloid Leukemia 영역에서 개발·상용화 중입니다. 작용기전: targeting B cell maturation antigen. Phase 1 안전성·PK 탐색 단계입니다. PFS: 0.99. 차별점: novel bridging strategies to eliminate MRD and enable transplant are urgently needed.
구조화 카탈로그 레코드입니다. Curated Core만큼 깊게 검토되지 않았습니다.
구조화 데이터
FRα
AML; Refractory/Relapse Acute Myeloid Leukemia
Recruiting
2026-08-19
Data Confidence · Medium
Development Signal · Watch
bispecific antibodies, and chimeric antigen receptor T cells
lentiviral expression vector and removed epitope tags used to discriminate between CAR and
humanized antibody capable of recognizing both LILRB3 and LILRB4
novel bridging strategies to eliminate MRD and enable transplant are urgently needed
targeting B cell maturation antigen
cytokine release syndrome occurred on day 3 and resolved with management; no neurotoxicity was observed
biomarker-driven methods were among the clinically orientated themes that emerged from foundational and precl
resistance to dominant suppressive pathways such as TGF-β and adenosine signalling, improved trafficking and tissue penetration
구조화 데이터
xenograft-bearing NSG mice
mouse
PD
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.